KAI Pharmaceuticals Announces Initiation of Second Phase 2 Study of KAI-4169
News Jan 09, 2012
The single-arm, open-label, multicenter, dose-titration study is designed to evaluate the effect of three times weekly intravenous bolus administration of KAI-4169 over a 12-week treatment period as assessed by percent change in parathyroid hormone (PTH) from baseline at the end of treatment. Secondary endpoints include proportion of subjects with greater-than or equal to 30% reduction in PTH from baseline, the proportion of subjects with PTH less-than or equal to 300 pg/mL and the mean change from baseline in serum calcium and phosphorus.
Steven James, President and CEO of KAI, commented, "We are proud of the momentum and continued progress of KAI-4169, our lead program. We recently reported results of the first Phase 2 study of KAI-4169 at the annual meeting of the American Society of Nephrology in a late breaker poster presentation. We believe KAI-4169 may lead to greatly improved care for patients, and we look forward to reporting continued positive results and progress of our program."
A new study has identified a drug that potentially could make a common type of immunotherapy for cancer even more effective. The study in laboratory mice found that the drug dasatinib, which is FDA-approved to treat certain types of leukemia, greatly enhances responses to a form of immunotherapy that is used against a wide range of other cancers.
15th International Conference on Surgical Pathology and Cancer Diagnosis
Apr 15 - Apr 16, 2019